Skip to main content

Upadacitinib Pregnancy and Breastfeeding Warnings

Brand names: Rinvoq

Upadacitinib Pregnancy Warnings

In animal studies, this drug administered at exposures equal to or greater than approximately 1.6 and 15 times the maximum recommended human dose (MRHD), respectively, resulted in dose-related increases in skeletal malformations, an increased incidence of cardiovascular malformations, increased post implantation loss, and decreased fetal body weights. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

This drug should not be used during pregnancy. Some authorities consider it contraindicated.

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Risk Summary: Based on animal studies, this drug can harm a developing fetus. Data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with rheumatoid arthritis. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth.

-Based on animal studies, this drug has the potential to adversely affect a developing fetus.
-Adequate methods of contraception should be encouraged.
-Verify negative pregnancy status in females of reproductive potential prior to initiating therapy.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Advise female patients of reproductive potential to use effective contraception during therapy and for 4 weeks after.

See references

Upadacitinib Breastfeeding Warnings

Use is not recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

-Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during therapy and for 6 days (approximately 10 half-lives).

See references

References for pregnancy information

  1. Product Information. Rinvoq (upadacitinib). AbbVie US LLC. 2019.

References for breastfeeding information

  1. Product Information. Rinvoq (upadacitinib). AbbVie US LLC. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.